Stockreport

IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025

Imunon, Inc.  (IMNN) 
PDF LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunother [Read more]